- Portola Pharmaceuticals (NASDAQ:PTLA) Q3 results (): Revenue: 14.2 (+273.7%); Andexxa sales: 7.7.
- More news on: Portola Pharmaceuticals, Healthcare stocks news, Earnings news and commentary, Stocks on the move, Read more ...
Market Wire News is a media platform, the information on this page was provided by SeekingAlpha via Quote Media. Read our full disclaimer.
When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
News, Short Squeeze, Breakout and More Instantly...
Portola Pharmaceuticals Inc. Company Name:
PTLA Stock Symbol:
Market:
Portola Pharmaceuticals Inc. Website:
SOUTH SAN FRANCISCO, Calif. , May 18, 2020 /PRNewswire/ -- Portola Pharmaceuticals, Inc. ® (NASDAQ: PTLA) today announced that, due to the public health impact of the coronavirus (COVID-19) pandemic and to prioritize the health and well-being of stockholders, employees and othe...
SOUTH SAN FRANCISCO, Calif. , May 14, 2020 /PRNewswire/ -- Portola Pharmaceuticals, Inc. ® (Nasdaq: PTLA) announced that the U.S. Centers for Medicare & Medicaid Services (CMS) has proposed extending the New Technology Add-on Payment (NTAP) for Andexxa ® [coagula...
SOUTH SAN FRANCISCO, Calif. , May 11, 2020 /PRNewswire/ -- Portola Pharmaceuticals, Inc. ® (Nasdaq: PTLA) today reported financial results for the three months ended March 31, 2020, and provided a corporate update, including the Company's actions to continue to su...